UroMems
Summary active Updated May 14, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
About
UroMems is a Grenoble, France-based medical device company developing UroActive, the first smart active implant for stress urinary incontinence (SUI) 12. The device uses a MyoElectroMechanical System (MEMS) placed around the urethral duct that automatically responds to patient activity without manual adjustments 12. The $60M strategic investment announced May 13, 2026 was financed entirely by U.S.-based Ajax Health Fund I to fund the SOPHIA2 pivotal clinical trial across 21 US and French investigational centers in preparation for FDA and EU regulatory submissions 12. Ajax Health partner David Beylik and Dr. Jeremy Durack joined the UroMems board 1. The round follows a $47M Series C completed in June 2024 led by Crédit Mutuel Innovation 1.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-05-13 | Growth (strategic) | $60M | Ajax Health Fund I | — 12 |
| 2024-06 | Series C | $47M | Crédit Mutuel Innovation | — 1 |
What Investors Say
No independently sourced investor quotes found at this time.
What Founders Say
No independently sourced founder quotes found at this time.
Sources
-
PR Newswire, “UroMems Raises $60 Million Strategic Investment from U.S.-Based Ajax Health Fund I,” May 13, 2026. Accessed May 2026. https://www.prnewswire.com/news-releases/uromems-raises-60-million-strategic-investment-from-us-based-ajax-health-fund-i-302771142.html↩↩↩↩↩↩↩
-
MassDevice, “UroMems raises $60M to support clinical trials for smart urology implant,” May 14, 2026. Accessed May 2026. https://www.massdevice.com/uromems-raises-60m-to-support-clinical-trials-for-smart-urology-implant/↩↩↩↩